With a PC and some software you can generate realistic projections that save time and money.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
A probability sampling assessment by FDA takes a look at compliance in the medical device world.
Step-by-step process for budgeting global trials that uses a Currency Risk Management method.
Even before trials start, compiling a "target label" can add value by helping steer product development.
An evaluation of the Munich Pilot and the affects of the EHR-EDC integration solution.
How the ability to apply text mining and signal detection algorithms to social media's real-time data provides unheard of value.
A rising initiative in Wales led by the International Business of Wales (IBW) promotes company growth in the region.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
Incorporating original study design accelerates better development decisions.
Understanding and using adaptive trial design to achieve the most of its available advantages.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
It is time for mandatory certification to be required for everyone involved in a clinical study.
How simulation can help in the planning and implementation of adaptive clinical trials.
An evaluation of the Munich Pilot and the affects of the EHR-EDC integration solution.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
A new study by Premier Research shows that both American and European pharmaceutical companies are facing similar problems in regards to pediatric trial regulations.
Step-by-step process for budgeting global trials that uses a Currency Risk Management method.
Roadmap of twists and turns that lie ahead following most recent draft issued in September.
A concise look at this nontraditional approach to clinical studies that explains the how and why of it.
With a PC and some software you can generate realistic projections that save time and money.
Lessons learned from FDA’s current process and proposed alternative review strategies.
Creating a drug's safety profile through the use of benefit-risk assessments during development.
Validating protocols and identifying investigators with secondary data sources.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
An evaluation of the Munich Pilot and the affects of the EHR-EDC integration solution.
Analysis of hematology and blood chemistry's AEs in sponsor's databases.
The availability of FHIR-based APIs enabling patients to access and use their healthcare data for multiple purposes has opened a door to an entirely new world of opportunities for partnering with patients on clinical studies.